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Introduction: Information is limited regarding health-related qual-
ity of life (QOL) status of long-term (greater than 5 years) lung
cancer survivors (LTLCS). Obtaining knowledge about their QOL
changes over time is a critical step toward improving poor and
maintaining good QOL. The primary aim of this study was to
conduct a 7-year longitudinal study in survivors of primary lung
cancer which identified factors associated with either decline or
improvement in QOL over time.
Methods: Between 1997 and 2003, 447 LTLCS were identified and
followed through 2007 using validated questionnaires; data on
overall QOL and specific symptoms were at two periods: short-term
(less than 3 years) and long-term postdiagnosis. The main analyses
were of clinically significant changes (greater than 10%) and factors
associated with overall QOL and symptom burden for each period
and for changes over time.
Results: Three hundred two (68%) underwent surgical resection
only and 122 (27%) received surgical resection and radiation/
chemotherapy. Recurrent or new lung malignancies were observed
in 84 (19%) survivors. Significant decline or improvement in overall
QOL over time were reported in 155 (35%) and 67 (15%) of 447
survivors, respectively. Among the 155 whose QOL declined, sig-
nificantly worsened symptoms were fatigue (69%), pain (59%),
dyspnea (58%), depressed appetite (49%), and coughing (42%). The
symptom burden did not lessen among the 67 who reported im-
provement in overall QOL, suggesting that survivors had adapted to
their compromised physical condition.
Conclusions: LTLCS suffered substantial symptom burden that
significantly impaired their QOL, indicating a need for targeted
interventions to alleviate their symptoms.
Key Words: Lung cancer, Long-term survivors, Health-related
quality of life, Symptoms, Pain, Dyspnea, and Fatigue.
(J Thorac Oncol. 2012;7: 64–70)
Individuals who are alive more than 5 years after lung cancerdiagnosis are referred to as long-term lung cancer survivors
(LTLCS).1 In the United States, approximately 26,000 indi-
viduals become LTLCS annually. According to the published
literature regarding health-related quality of life (QOL),
LTLCS do not experience the same QOL as their age-
matched survivors of other cancers; they scored the lowest in
health care utility among long-term survivors of all cancers; and
one in every four LTLCS is significantly restricted in physical
ability or suffering from depressive symptoms.1 Reasons for
LTLCS’ degraded QOL are poorly characterized, particularly
their persistently compromised lung capacity, treatment-related
morbidity, and heavy symptom burden. Unfortunately, changes
in QOL over time or the characteristics associated with these
changes have rarely been evaluated in LTLCS. This study was
designed to identify potential targets for future interventions
which could be tailored to improve poor and maintain good
QOL among LTLCS with specific aims to characterize QOL
over a 7-year period, to describe QOL changes over time, and to
identify factors associated with progressively compromised or
enhanced QOL.
MATERIALS AND METHODS
The primary objectives were (1) to describe the overall
QOL and main symptom burden of LTLCS and to examine
changes overtime and (2) to characterize QOL and symptom
burden at two point periods, i.e., within 3 years and beyond
5 years after primary lung cancer diagnosis. Secondary ob-
jectives included (1) to identify factors associated with de-
clining QOL measures over time and (2) to evaluate the
potential impact of missing data.
Subjects
Since 1997, all patients with a pathologic diagnosis of
primary lung cancer evaluated and treated at Mayo Clinic,
Rochester, Minnesota, have been prospectively enrolled and
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followed for outcome research, using protocols approved by
the Mayo Clinic Institutional Review Board, and all human
participants have written informed consent.2 Between Janu-
ary 1997 and May 2003, 6252 new primary lung cancer cases
were identified and pathologically confirmed. The follow-up
process started within 6 months after diagnosis and then
annually until patients’ death. More details have been de-
scribed in our previous publications.3,4 By December 2007,
869 patients (14%) were verified as LTLCS who returned at
least one follow-up questionnaire (any time postdiagnosis).
Six hundred sixty-nine (77.0%) answered a QOL question-
naire at least once beyond 5 years, and 447 (66.8%) have
answered the questionnaire at least twice, one within 3 years
and another beyond 5 years after lung cancer diagnosis,
forming the basis for all results in this study.
Information from Questionnaire
QOL measures were chosen based on their relevance to
general health and QOL, psychometric properties among
cancer survivors, ease of administration, and low-respondent
burden. The Lung Cancer Symptom Scale (LCSS) is a dis-
ease- and site-specific symptom burden assessment focusing
on the symptom and function of patients with lung cancer.5,6
The LCSS consists of two parts, and only the patient scale
was used in this study. The patient scales consist of nine
items and are worded (and abbreviated in the analysis) as
follows1: How is your appetite (appetite)?2 How much fatigue
do you have (fatigue)?3 How much coughing do you have
(cough)?4 How much shortness of breath do you have (dys-
pnea)?5 How much blood do you see in your sputum (he-
moptysis)?6 How much pain do you have (pain)?7 How bad
are your symptoms from lung cancer (lung cancer symptom
distress)?8 How much has your illness affected your ability to
carry out normal activities (illness affecting normal activi-
ties)?9 How would you rate your quality of life today (overall
QOL)? The intensity of patient responses is measured by
visual analog scales.6,7 In an earlier study, internal consis-
tency was high (Cronbach   0.89).8
Information from Medical Records
Information abstracted from participants’ medical re-
cords included demographics, lung cancer histology, staging,
anatomical location, and treatment. Tobacco history informa-
tion included current or previous use, duration, average
amount of cigarettes smoked per day, and years since the
participant quit smoking. For participants who received med-
ical care outside Mayo Clinic, copies of the relevant medical
records were acquired and reviewed. Further details regard-
ing pathology and treatment classifications have been previ-
ously published.2,3,9 To avoid misclassification, we reported
the occurrence of disease progression, recurrent disease, and
second primary lung cancer together.4
Measurements and Analyses
Overall QOL (item 9 of LCSS) and symptoms (items
1–8) were assessed as scales varying from 0 (worst) to 100
(best) and as a binary variable. Normative data for overall
QOL in healthy individuals establish 80 as the mean and 20
as the standard deviation (SD); one-half SD has been con-
ventionally used to define the normative range, i.e., mean 
1⁄2 SD.10–14 A clinically important decline or improvement is
defined as a greater than 10-point or 10% change; poor QOL
was defined as less than 50 on the 100-point scale.15 Profile
analysis to model the longitudinal trend over time via re-
peated measures analysis of variance was used.16
Overall QOL was also assessed at two time points by
nonparametric tests: short-term (within 3 years of diagnosis)
and long-term (more than 5 years postdiagnosis) follow-up,
for each time period and for changes over the two. A
clinically important decline or improvement was tested by 2
or Fisher’s exact test tests.17 Rank transformed QOL scores
were used but remarkably consistent with the results obtained
by using the original scores; therefore, models using original
scores were presented. Both multiple logistic and linear
regression models were developed to determine which cova-
riates were associated with poor (binary) and worse (a con-
tinuous variable) overall QOL, respectively, via a stepwise
procedure for covariate selection. For secondary objectives,
comparing patients’ average QOL between short-term and
long-term responses, a standard Wilcoxon test has 80%
power to detect a difference of 0.25 SD based on 447 patients.
Since the extent of surgical resection, e.g., lobectomy versus
pneumonectomy may impact patients’ QOL measures, we
have evaluated a subset of patients who had only surgery as
treatment.
Evaluation of Missing Data and Potential
Selection Bias
We compared the following three groups: patients who
responded at both time points (n  447), patients who only
answered a short-term or a long-term (n  422) question-
naire, and patients who never responded (n  309), with
regard to the following variables: age at diagnosis; sex;
race/ethnicity; education; smoking status; tumor, node, and
metastasis stage; histology; and primary treatment. Supple-
mentary Table S1 (http://links.lww.com/JTO/A196) provides
basic descriptive information of the three subgroups of sur-
vivors. The impact of these differing characteristics on QOL
results was evaluated.
RESULTS
Primary Results: I. Basic Descriptive
Information
Description of the Survivors
Among the 447 LTLCS, the mean age at the time of initial
lung cancer diagnosis was 65 years in men (n  223) and 63
years in women (n  224), p  0.01. Table 1 presents more
detailed demographic information by gender with regard to race
and ethnicity (greater than 90% of the total were Whites),
education level (57% had greater than 12 years of education),
marital status (79% married), employment status (42% em-
ployed), and cigarette smoke exposure history including second-
hand smoking (82% former or current smokers). Additional
information regarding tumor histology, lung cancer stage, co-
morbidities, and treatment are provided in Supplementary Ta-
bles S2 and S3 (http://links.lww.com/JTO/A196). Recurrent
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lung cancer or new lung malignancies (disease-bearing) were
observed in 84 (19%) survivors (Supplementary Table S2,
http://links.lww.com/JTO/A196). Three hundred two patients
(68%) undertook surgical resection only, 122 (27%) received
combinational treatment (surgery plus radiation or chemother-
apy), and 23 (5%) had nonsurgical treatment (Supplementary
Table S3, http://links.lww.com/JTO/A196).
QOL and Symptom Burden of the Survivors
The mean scores and SDs at seven time points, i.e., 1 to
7 years after lung cancer diagnosis and the trend for each
scale, varied from 81 20 (year 2) to 75 21 (year 7). After
adjusting for multiple factors listed in Table 1 and Supple-
mentary Tables S2–S3 (http://links.lww.com/JTO/A196), the
mean scores remained virtually the same for all scales, but the
SD was reduced by 55 to 67% (data not shown). Symptom
subscales that consistently scored low throughout the 7 years
were fatigue (scores varying 57–67) and dyspnea (59–69);
subscales that consistently scored higher than 80 were lung
cancer symptom distress (86–88) and hemoptysis in partic-
ular (95–97). As shown in Figure 1, changing mean overall
QOL from 81 in year 2 to 75 in year 6 did not reach the level
of clinically important decline; however, specific scales that
met clinically important decline over time included pain,
fatigue, and dyspnea: particularly, fatigue and dyspnea
dropped to under 60, a level indicative of serious impairment.
To assess the impact on QOL by the extent of surgical
resection of primary lung cancer, mean scores of overall and
specific symptom scales were compared between patients
who received lobectomy (73.5%) and who received more
extensive resections (15.6%, bilobectomy, pneumonectomy,
completion pneumonectomy, and sleeve lobectomy). We ob-
served somewhat worse mean scores for several scales, par-
ticularly fatigue, coughing, and dyspnea; however, none were
more than 10-point or 10% difference.
Primary Results II. QOL and Symptom Burden
Change Over Time
The clinically important decline and improvement in
overall QOL over time were reported in 35% and 15%,
respectively, of the 447 survivors (Supplementary Figure
S1A, http://links.lww.com/JTO/A196). No striking difference
was observed between the 363 disease-free survivors and the
84 disease-bearing survivors regarding the proportions with
clinically important change over time (Supplementary Fig-
ures S1B–S1C, http://links.lww.com/JTO/A196). Table 2
presents change over time of overall QOL and the subscales
among all 447 survivors. The clinically important decline in
scores was primarily confined within the patient’s assessment
of symptoms; specifically, we observed 15 points worse in
fatigue (in 47% of survivors), 14 points worse in pain (43%),
and 12 points worse in dyspnea (44%).
Among the 155 LTLCS who reported a clinically im-
portant decline in overall QOL, five symptom scales dropped
in larger magnitude and higher percentage: fatigue (24-point
decline in 69% of the 155), pain (23-point decline in 59%),
dyspnea (20-point decline in 58%), appetite (11-point decline
in 49%), and coughing (12-point decline in 42%); six of the
eight subscales had 10 points or more decline. In sharp
contrast, among the 67 survivors who reported a significant
improvement (by 19-point increase) in overall QOL, no
specific symptom or functional domain increased by greater
than 10 points; moreover, the six symptom subscales had
minimal or no increase or even numerically declined (pain,
coughing, and dyspnea). Figure 2 illustrates the contrasting
changes over time of subscales among individuals with a
clinically important decline in overall QOL (left panel) and
individuals with a clinically important improvement in over-
all QOL.
TABLE 1. Selected Descriptive Data by Sex among 447
Long-Term Lung Cancer Survivors
Female,
n  224
(50.1%)
Male,
n  223
(49.9%)
Total,
n  447
p
(F vs. M)
Age at diagnosis
Mean age in
years (SD)
62.7 (10.6) 64.9 (10.3) 63.8 (10.5) 0.01
Race/ethnicity 0.19
Caucasian 205 (91.5) 204 (91.5) 409 (91.5) 0.21b
Hispanic 1 (0.4) 5 (2.2) 6 (1.3)
Alaskan/American
Indian
16 (7.1) 14 (6.3) 30 (6.7)
Black 2 (0.9) 0 (0.0) 2 (0.4)
Years of education
12 yr 99 (45.2) 89 (40.1) 188 (42.6) 0.19
13–16 yr 81 (37.0) 78 (35.1) 159 (36.1)
16 yr 39 (17.8) 55 (24.8) 94 (21.3)
Marital status at
diagnosis
Married 163 (73.4) 187 (84.6) 350 (79.0) 0.01
Othera 59 (26.6) 34 (15.4) 93 (21.0)
Employment at
diagnosis
0.01
Unemployed 2 (0.9) 2 (0.9) 4 (0.9) 0.01b
Employed 93 (41.5) 95 (42.6) 188 (42.1)
Retired 105 (46.9) 126 (56.5) 231 (51.7)
Homemaker 24 (10.7) 0 (0.0) 24 (5.4)
Smoking status
Never smoker 56 (25.0) 26 (11.7) 82 (18.3) 0.01
Former smoker 103 (46.0) 137 (61.4) 240 (53.7)
Current smoker 65 (29.0) 60 (26.9) 125 (28.0)
Pack-years (ever
smokers)
20 40 (24.0) 35 (17.9) 75 (20.7) 0.02
20–39 53 (31.7) 45 (23.0) 98 (27.0)
40 74 (44.3) 116 (59.2) 190 (52.3)
SHS exposure (never
smokers)
0.52
Not exposed 10 (17.9) 6 (24.0) 16 (19.8) 0.55b
Exposed 46 (82.1) 19 (76.0) 65 (80.2)
a Includes single, divorced, and widowed.
b Fisher’s exact test for small expected cell counts.
SHS, second-hand smoking.
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Secondary Results I: Predictive Models of QOL:
Short Term, Long Term, and Over Time
Participants’ characteristics listed in Table 1 and Sup-
plementary Tables S2-S3 (http://links.lww.com/JTO/A196)
were included in the analyses for both follow-up periods, side
by side (Table 3). Under a multiple logistic regression model,
factors significantly associated with a poor overall QOL at
short-term follow-up were male gender, squamous cell
carcinoma, and poor fatigue and pain scores; at long-term
follow-up, they were older age; lung cancer progression or
recurrence; and poor scores in fatigue, dyspnea, and pain.
Similar results were found under the alternative multiple
linear regression models (Supplementary Table S4,
http://links.lww.com/JTO/A196).
The same analyses were performed to identify patients
who had significant change over time: contributing factors to
a clinically significant decline in overall QOL scores were
more than 16 years of education and clinically significant
declines in fatigue and pain (Supplementary Table S5,
http://links.lww.com/JTO/A196, middle column); whereas,
additional factors associated with an improved overall QOL
(Supplementary Table S5, http://links.lww.com/JTO/A196,
right column) were sex, comorbid conditions of nonlung
diseases (e.g., cardiovascular, cerebral, other malignant dis-
eases, and diabetes), and a clinically significant improvement
in fatigue, dyspnea, and pain scales.
Secondary Results II: Potential Impact of
Missing Value on Study Results
We have reported four factors that were significantly
different between the 447 study participants and the potential
study subjects who were eligible but were not included due to
nonparticipation or missing data (Supplementary Table S1,
http://links.lww.com/JTO/A196). Specifically, the study sam-
ple was enriched with highly educated never smokers who
had resected adenocarcinoma or carcinoid or salivary gland
tumors, all with better overall QOL scores. The impact of
these four factors on overall scores of QOL (Supplementary
Table S6, http://links.lww.com/JTO/A196) demonstrated a 4-
to 12-point difference across subgroups, no matter if the
overall QOL was taken at the first response or an average of
all responses for each subject. Given the characteristics of
study participants who in general reported a better overall
QOL, the eligible subjects who were not included in this
study were likely to have an unfavorable overall QOL;
therefore, our results may underreport the true magnitude of
compromised QOL in LTCLS.
FIGURE 1. Mean overall QOL of
LTLCS* at one to 7 years postdiag-
nosis. *LTLCS: 447 long-term lung
cancer survivors who answered the
QOL questionnaire on 3- and
5-year follow-ups. All scales are
measured 0 (worst) to 100 (best).
†p values are from profile analysis
test for flatness, indicative of trend
over time.
TABLE 2. Overall QOL and Symptom Scalesa of 447 Long-
Term Lung Cancer Survivors
Median Score Changes Over Time (%)
<3 yr >5 yr Change Decline No Change Improve
Overall QOL 85 78 7 34.7 50.3 15.0
1. Pain 94 80 14 43.4 45.4 11.2
2. Fatigue 69 54 15 47.2 39.7 13.1
3. Coughing 86 80 6 33.3 49.9 16.9
4. Dyspnea 72 60 12 43.9 41.2 14.9
5. Appetite 87 82 5 33.8 52.3 13.8
6. Hemoptysis 99 98 1 4.6 91.8 3.6
7. Lung cancer
symptom
distress
94 94 0 16.5 68.6 14.9
8. Illness
affecting
normal life
88 86 2 24.7 61.9 13.4
a All scales are measured 0 (worst) to 100 (best). Rows in italic font (pain, fatigue,
and dyspnea) were reported to be clinically important decline or improvement (10% or
higher) between the two time points.
QOL, quality of life.
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TABLE 3. Factorsa Associated with Poorb Overall QOL at each Time Point (Logistic Regression)
<3 yr Follow-Up >5 yr Follow-Up
Characteristics OR (95% CI) p OR (95% CI) p
Age diagnosis (vs. 55)
55–74 —c — 1.39 (0.46–4.18) 0.563
75 — — 5.18 (1.58–16.95) 0.007
Sex (vs. female)
Male 3.20 (1.01–10.13) 0.048
Cell type (vs. adeno/BAC) — —
Squamous 5.81 (1.67–20.19) 0.006
Other NSCLC 4.87 (0.95–25.13) 0.059
Small cell 1.34 (0.05–37.87) 0.863
Carcinoid/salivary 2.87 (0.53–15.45) 0.221
Progression/recurrence/second
primary (vs. none)
Any — — 2.68 (1.29–5.58) 0.008
Fatigue subscale (vs. not poor)
Poor 11.88 (4.07–34.70) 0.001 3.53 (1.52–8.20) 0.003
Dyspnea subscale (vs. not poor)
Poor — — 2.79 (1.27–6.12) 0.011
Pain subscale (vs. not poor)
Poor 41.48 (10.82–159.02) 0.001 2.11 (0.99–4.50) 0.052
a Includes the fatigue, dyspnea, and pain subscales.
b Poor overall QOL or subscale is defined as a response 50 points.
c Not a significant factor in this model.
QOL, quality of life; BAC, bronchioloalveolar carcinoma; NSCLC, non-small cell lung cancer; OR, odds ratio; CI,
confidence interval.
FIGURE 2. Subscales of survivors
with declined (n  155, A) or im-
proved (n  67, B) overall QOL.
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DISCUSSION
Health-related quality of life has been identified by
cancer survivors to be as important as survival length (quan-
tity).18,19 This study is the first to prospectively characterize
QOL and symptom burden in a large and recent cohort of
LTLCS (N  447) who were alive beyond 5 years post-
diagnosis.1 Based on self-reported QOL assessments between
two time periods, significant decline in overall QOL was
observed in 35% of the LTLCS, and significant improvement
in overall QOL was observed in only 15% of the survivors.
Interestingly, a similar percentage of decline was observed in
both disease-free and disease-bearing survivors, suggesting that
cancer recurrence and progression are not the only factors that
impact QOL in LTLCS. Among the survivors with degraded
overall QOL, almost all specific symptom scales exceeded a
10% reduction or clinically important decline: pain, fatigue,
coughing, dyspnea, and appetite. Therefore, QOL of LTLCS
showed substantial deficits relative to other cancer survivor
populations, as evidenced by our findings and a concise over-
view below.
Investigations involving many tumor types have iden-
tified how factors unrelated to the disease can impact cancer
survivors’ overall QOL, particularly surrounding the time of
treatment and shortly thereafter.20–26 There were a small
number of tumor types where survivors reported improved
QOL through finding meaning and purpose in life since being
diagnosed with cancer. Specifically, long-term survivors of
breast cancer or lymphoma reported comparable or better
QOL than their healthy age-matched controls, which has been
summarized in multiple studies involving approximately
4000 adult cancer survivors.27 Ferrell et al.20 studied 687
cancer survivors and reported that all QOL components were
positively impacted. Ashing-Giwa et al.21 reported findings
from 278 breast cancer survivors, showing comparable or
better QOL than healthy age-matched controls. Ganz et al.22
also reported high levels of functioning and QOL in 914
breast cancer survivors. Mosconi et al.23 demonstrated that
the QOL among 1772 long-term breast and colon cancer
survivors seems to be the same as healthy populations. For
breast cancer patients who have a successful outcome in
terms of reconstructive surgery, they are virtually indistin-
guishable from healthy people of their overall QOL.
In contrast, outcome research in lung cancer has been
focused mainly on short-term survival and QOL. The lack of
published LTLC survivorship research has only recently been
recognized as an important deficit. A cross-sectional study of
QOL in LTLCS has shown that objective measures of demo-
graphic and clinical factors alone cannot explain a large
amount of variance in the total QOL scores, while self-
reported distressed mood was the most important predictor of
QOL.24 A prospective longitudinal approach is required to
consider the changes and effectively evaluate the multiple
factors that affect QOL in LTLCS, which was the design and
aims of the current study. We observed that the overall QOL
score within 3 years of diagnosis was around 80, which is
equivalent to healthy populations,25 and then decreased to 75
after 4 years postdiagnosis. This is consistent with the con-
cept that even among the best performers among LTLCS,
QOL declines over time and warrants more attention.
Symptoms related to higher death rates were observed
during years 1 to 4 after diagnosis28,29; our current study
results highlighted the deteriorating QOL associated with
these symptoms. Specifically, our results show that most
symptom scales declined over time except hemoptysis, lung
cancer symptom distress, and illness affecting normal activ-
ities. This is consistent with the concept that symptoms
related to treatment dissipate over time; however, other
symptoms particularly fatigue and dyspnea dropped (wors-
ened) to less than 60, indicative of serious impairment and
demands further understanding the physical and biological
mechanisms, which in turn could lead to targeted interventions
to improve QOL. Such targeted interventions, which are to be
identified and evaluated, should start early in the course of
surviving lung cancer, as evidenced by our independent analyses
of symptom clusters within 5 years postdiagnosis.28,29
Noted were the small subset of survivors (15%) in our
study who reported an improved QOL overtime. However,
when looking beyond the overall QOL and into the specific
symptom scales, coughing, dyspnea, and pain actually de-
creased 4, 3, and 2 points, respectively. This paradoxical
phenomenon suggests that QOL of survivors may be affected
by a myriad of factors, which may reflect differently in a
subjective evaluation of QOL and on observed health status.
Discrepancies seen in measures of self-reported versus observed
levels of physical functioning and objective health status or
well-being has led to the recognition of response shift, i.e.,
changes in internal standard of reference, values, and reconcep-
tualization of the target construct in QOL studies.26,27
Our study also found that surgical resections that are
more extensive than standard lobectomy, such as bilobec-
tomy and pneumonectomy, may negatively impact patients’
symptom burdens and QOL; however, the negative impact
from major resections, although on average not reaching the
threshold of clinical significance, were present in both short-
term and long-term follow-up periods.
Another inherent drawback of QOL studies is survival
bias, coupled with nonparticipation bias. These biases are
encountered in a study such as this one due to the severity of
the illness (i.e., advanced stage lung cancer). Missing data
and nonparticipation may affect the validity of the study
results. A critical issue is whether respondents and nonre-
spondents differ systematically and whether investigators
are fully aware of the potential biases. In our study, we
have carefully evaluated characteristics (Supplementary
Table S1, http://links.lww.com/JTO/A196) and identified the
magnitude of point changes in QOL associated with each
potential confounding factor (Supplementary Table S6,
http://links.lww.com/JTO/A196). A consensus was a poten-
tial underestimation of compromised QOL among LTLCS
because missing data and nonparticipation were significantly
overrepresented in subgroups with more severe disease and
higher mortality. This nonrandom missing phenomenon has
been well addressed in previous studies, either focusing on
symptom patterns during the first year after lung cancer
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diagnosis30–33 or in evaluating symptom clusters up to 5 years
postdiagnosis.28,29
Although the LCSS is a well-recognized QOL tool,
other scales have been available; in particular, specific scales
for anxiety or depression such as HADS-D, HADS-A, PHQ-9,
and CES-D34–36 might have been useful to more precisely
capture the emotional health of these patients and better discrim-
inate the mental health status of disease-free survivors from
disease-bearing survivors. These more mood-focused psychos-
ocial tools have been recently evaluated in subgroups of patients
and data should be mature in future analyses.
To conclude, self-reported QOL of LTLCS showed sub-
stantial deficits; affected domains were mainly in symptom
burden, indicating a demand for targeted interventions for im-
proved QOL. There is a need to identify and intervene with
subgroups of LTLCS who are at an elevated risk of diminished
QOL soon after receiving a lung cancer diagnosis and undergo-
ing cancer treatment. Further understanding is needed as to the
mechanisms of progression of symptoms and loss of function.
Accurate knowledge including risk estimation for medical
events is critical to the long-term management of lung cancer
survivors and to timely evaluate treatment strategies.
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